鞍石生物科创板IPO获得受理，拟募资24.5亿元

Core Viewpoint - Ansh Biotechnology Co., Ltd. has received acceptance for its IPO on the Sci-Tech Innovation Board, aiming to raise 2.45 billion yuan for its innovative biopharmaceuticals focused on unmet clinical needs in oncology [1] Company Overview - Ansh Biotechnology is an innovative biopharmaceutical company that has entered the commercialization stage, focusing on high-quality innovative anti-tumor drugs to improve patients' quality of life [1] - The company has chosen to apply for listing under the criteria specified in Article 2.1.2 (5) of the Sci-Tech Innovation Board listing rules [1] Financial Performance - The financial data for Ansh Biotechnology shows the following projected revenues and net profits: - 2022: Revenue of approximately 0 million yuan, net profit of approximately -163.68 million yuan - 2023: Revenue of approximately 12.96 million yuan, net profit of approximately -282.72 million yuan - 2024: Revenue of approximately 71.66 million yuan, net profit of approximately -478.71 million yuan - Q1 2025: Revenue of approximately 64.04 million yuan, net profit of approximately -9.17 million yuan [1] Product Development - As of the date of the prospectus, Ansh Biotechnology's main product, Wanbi Rui (Bertinib), has received approval for three indications in China, while another product, Andai Aitini, has successfully submitted a new drug application and has been granted priority review status [1]